 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.             *hb0279*      
HOUSE BILL 279  
E5   6lr0096  
  (PRE–FILED)  CF SB 196  
By: Chair, Health Committee (By Request – Departmental – Public Safety and 
Correctional Services)  
Requested:  September 16, 2025  
Introduced and read first time: January 14, 2026  
Assigned to: Health  
 
A BILL ENTITLED  
 
AN ACT concerning  1 
 
Correctional Services – Medication Review Committee – Administration of 2 
Psychotropic Medication to an Incarcerated Individual  3 
 
FOR the purpose of authorizing the establishment of a medication review committee within 4 
the Department of Public Safety and Correctional Services that convenes to 5 
determine whether to approve the administration of psychotropic medication to a 6 
certain in carcerated individual under certain circumstances; providing that 7 
psychotropic medication may not be administered to an incarcerated individual who 8 
refuses the medication except under certain circumstances; providing for the 9 
membership and operating proced ures of a medication review committee; 10 
establishing certain rights of an incarcerated individual in connection with the 11 
convening of a medication review committee; establishing procedures for a certain 12 
administrative review and appeal of the decision of a medication review committee; 13 
requiring a certain treating practitioner to document certain matters under certain 14 
circumstances; and generally relating to medication review committees.  15 
 
BY adding to  16 
 Article – Correctional Services  17 
 Section 9 –619 18 
 Annotated Code of Maryland  19 
 (2025 Replacement Volume)  20 
 
 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 21 
That the Laws of Maryland read as follows:  22 
 
Article – Correctional Services  23 
 
9–619. 24 
2 HOUSE BILL 279   
 
  
 (A) (1) IN THIS SECTION THE F OLLOWING WORDS HAVE THE  MEANINGS 1 
INDICATED . 2 
 
  (2) “COMMITTEE ” MEANS A MEDICATION R EVIEW COMMITTEE 3 
ESTABLISHED IN ACCOR DANCE WITH THIS SECT ION THAT CONVENES TO  DETERMINE 4 
WHETHER TO APPROVE T HE ADMINISTRATION OF  PSYCHOTROPIC MEDICAT ION ON 5 
A NONEMERGENCY BASIS  TO AN INCARCERATED I NDIVIDUAL WHO REFUSE S TO 6 
ACCEPT PSYCHOTROPIC MEDICATION AS PRESCR IBED . 7 
 
  (3) “LAY ADVISOR ” MEANS AN INDIVIDUAL WHO IS KNOWLEDGEABLE  8 
ABOUT MENTAL HEALTH PRACTICE AND CAN ASS IST INCARCERATED IND IVIDUALS 9 
WITH UNDERSTANDING T HE PROCESS OUTLINED IN THIS SECTIO N. 10 
 
  (4) “LICENSED MENTAL HEALT H INFIRMARY ” MEANS A DESIGNATED 11 
UNIT WITHIN A STATE CORRECTIONAL FA CILITY THAT IS LICEN SED BY THE 12 
MARYLAND DEPARTMENT OF HEALTH AS A MENTAL HE ALTH INFIRMARY . 13 
 
 (B) THIS SECTION APPLIES ONLY TO LICENSED MEN TAL HEALTH 14 
INFIRMAR IES WITHIN STATE CORRECTIONAL FA CILITIES . 15 
 
 (C) PSYCHOTROPIC MEDICATI ON MAY NOT BE ADMINI STERED TO AN 16 
INCARCERATED INDIVID UAL WHO REFUSES THE MEDICATION , EXCEPT : 17 
 
  (1) IN AN EMERGENCY , ON THE ORDER OF A PR ACTITIONER WHEN 18 
THE INCARCERATED IND IVIDUAL PRESEN TS AN IMMINENT DANGE R TO THE LIFE OR 19 
SAFETY OF SELF OR OT HERS ; OR 20 
 
  (2) IN A NONEMERGENCY , IF THE TREATING PRAC TITIONER HAS 21 
RECOMMENDED THE INVO LUNTARY ADMINISTRATI ON OF PSYCHOTROPIC 22 
MEDICATION BECAUSE : 23 
 
   (I) THE INCARCERATED IND IVIDUAL HAS A MENTAL  DISORDER ; 24 
 
   (II) DUE TO THE MENTAL DI SORDER , THE INCARCERATED 25 
INDIVIDUAL IS UNABLE  TO FUNCTION IN GENER AL POPULATION WITHIN  A 26 
CORRECTIONAL FACILIT Y AND REQUIRES INPAT IENT CARE IN A LICEN SED MENTAL 27 
HEALTH INFIRMARY WIT HIN THE DEPARTMENT ; 28 
 
   (III) THE INC ARCERATED INDIVIDUAL  PRESENTS A DANGER TO  29 
THE LIFE AND SAFETY OF SELF OR OTHERS ; 30 
 
 HOUSE BILL 279  3 
 
    (IV) THE INCARCERATED IND IVIDUAL IS UNABLE OR  UNWILLING 1 
DUE TO A MENTAL DISO RDER TO GIVE INFORME D CONSENT TO THE 2 
ADMINISTRATION OF PS YCHOTROPIC MEDICATIO N; 3 
 
   (V) THERE A RE NO LESS RESTRICTI VE TREATMENT 4 
INTERVENTIONS , INCLUDING ENCOURAGIN G VOLUNTARY MEDICATI ON 5 
COMPLIANCE , CONSISTENT WITH THE WELFARE AND SAFETY O F THE INDIVIDUAL ; 6 
 
   (VI) THE USE OF PSYCHOTRO PIC MEDICATION IS CL INICALLY 7 
INDICATED AS THE MOS T APPROPRIATE TRE ATMENT FOR THE INCAR CERATED 8 
INDIVIDUAL ’S CONDITION ACCORDIN G TO CURRENT PRACTIC E FOR RESTORING OR 9 
PREVENTING FURTHER D ETERIORATION OF THE INCARCERATED INDIVID UAL’S 10 
MENTAL OR PHYSICAL H EALTH ; AND 11 
 
   (VII) A COMMITTEE HAS DETE RMINED , IN ACCORDANCE WITH 12 
THE PROVISIONS OF THIS S ECTION , THAT PSYCHOTROPIC ME DICATION SHOULD BE 13 
ADMINISTERED OVER TH E OBJECTION OF THE I NCARCERATED INDIVIDU AL. 14 
 
 (D) (1) A COMMITTEE SHALL CONS IST OF THE FOLLOWING  INDIVIDUALS 15 
APPOINTED BY THE DIRECTOR OF MENTAL HEALTH FOR THE DEPARTMEN T OR THE 16 
DIRECTOR ’S DESIGNEE : 17 
 
   (I) THE CHIEF PSYCHIATRI ST FOR THE REGION WH ERE THE 18 
LICENSED MENTAL HEAL TH INFIRMARY IS LOCA TED; 19 
 
   (II) ANOTHER PSYCHIATRIST ; AND 20 
 
   (III) A MENTAL HEALTH PROF ESSIONAL WHO IS NOT A 21 
PHYSICIAN . 22 
 
  (2) THE DIRECTOR OF MENT AL HEALTH OR THE DIRECTOR ’S 23 
DESIGNEE SHALL APPOI NT A CHAIR OF THE CO MMITTEE FROM AMONG I TS 24 
MEMBERS . 25 
 
  (3) AN INDIVIDUAL WHO IS DIRECTLY RESPONSIBLE  FOR 26 
IMPLEMENTING THE TRE ATMENT PLAN FOR THE INCARCERATED INDIVID UAL 27 
UNDER REVIEW MAY NOT  SERVE AS A MEMBER OF THE COMMITTEE . 28 
 
 (E) THE DIRECTOR OF MENTAL HEALTH OR THE DIRECTOR ’S DESIGNEE 29 
SHALL ASSIGN AN IMPA RTIAL LAY ADVISOR TO  ASSIST THE INCARCERA TED 30 
INDIVIDUAL WITH THE PROCESS SET FORTH IN  THIS SECTION . 31 
 
4 HOUSE BILL 279   
 
  (F) THE DIRECTOR OF MENTAL HEALTH OR THE DIRECTOR ’S DESIGNEE 1 
SHALL GIVE THE INCAR CERATED INDIVIDUAL A ND THE LAY ADVISOR W RITTEN 2 
NOTICE AT LEAST 10 BUSINESS DAYS BEFORE  CONVENING THE COMMIT TEE THAT 3 
SHALL INCLUDE THE FO LLOWING INFORMATION : 4 
 
  (1) THE DATE , TIME , AND LOCATION OF THE SCHEDULED COMMITTEE 5 
MEETING ; 6 
 
  (2) THE PURPOSE OF THE C OMMITTEE ; AND 7 
 
  (3) A COMPLETE DESCRIPTI ON OF THE RIGHTS OF AN INCARCERATED 8 
INDIVIDUAL UNDER SUB SECTION (G) OF THIS SECTION . 9 
 
 (G) IN CONNECTION WITH TH E CONVENING OF A COM MITTEE , AN 10 
INCARCERATED INDIVID UAL HAS THE RIGHT TO : 11 
 
  (1) ATTEND THE COMMITTEE  MEETING , EXCEPT FOR THE DISCU SSION 12 
CONDUCTED TO ARRIVE AT A DECISION ; 13 
 
  (2) PRESENT INFORMATION , INCLUDING WITNESSES ; 14 
 
  (3) ASK QUESTIONS OF ANY  PERSON PRESENTING IN FORMATION TO 15 
THE COMMITTEE ; 16 
 
  (4) REQUEST ASSISTANCE F ROM A L AY ADVISOR ; AND 17 
 
  (5) BE INFORMED OF : 18 
 
   (I) THE IDENTITY OF THE ASSIGNED LAY ADVISOR ; 19 
 
   (II) THE INCARCERATED IND IVIDUAL ’S DIAGNOSIS ; AND 20 
 
   (III) THE CLINICAL NEED FO R THE PSYCHOTROPIC M EDICATION , 21 
INCLUDING POTENTIAL SIDE EFFECTS AND MAT ERIAL RISKS AND BENEFITS OF 22 
TAKING OR REFUSING T HE MEDICATION . 23 
 
 (H) THE CHAIR OF A COMMIT TEE MAY : 24 
 
  (1) POSTPONE OR CONTINUE  THE COMMITTEE FOR GO OD CAUSE , FOR 25 
UP TO 7 DAYS ; AND 26 
 
  (2) TAKE APPROPRIATE MEA SURES NECESSARY TO C ONDUCT THE 27 
COMMITTEE IN AN ORDE RLY MANNER . 28 
 HOUSE BILL 279  5 
 
  
 (I) (1) BEFORE A COMMITTEE ME ETS, THE TREATING PSYCHIA TRIC 1 
PROVIDER SHALL PROVI DE A DETAILED REPORT  OF THE INCARCERATED 2 
INDIVIDUAL ’S MEDICAL RECORD TO INCLUDE : 3 
 
   (I) THE BASIS FOR THE RE QUEST TO ADMINISTER 4 
PSYCHOTROPIC MEDICAT ION ON A NONEMERGENC Y BAS IS; 5 
 
   (II) THE INCARCERATED IND IVIDUAL ’S DIAGNOSIS , BEHAVIORS 6 
OBSERVED , AND CURRENT MENTAL S TATUS ; 7 
 
   (III) A DESCRIPTION OF DAI LY FUNCTIONING ; 8 
 
   (IV) RECOMMENDED PSYCHOTR OPIC MEDICATION ; 9 
 
   (V) METHODS USED TO ENCO URAGE VOLUNTARY MEDI CATION 10 
ADHERENCE ; 11 
 
   (VI) VOLUNTARY AND INVOLU NTARY MEDICATION HIS TORY ; 12 
AND 13 
 
   (VII) A DESCRIPTION OF THE  LESS INTRUSIVE TREAT MENT 14 
ALTERNATIVES CONSIDE RED OR ATTEMPTED . 15 
 
  (2) THE REPORT SHALL BE D ISTRIBUTED TO THE CO MMITTEE 16 
MEMBERS NOT LESS THA N 72 HOURS BEFOR E THE COMMITTEE IS T O MEET . 17 
 
 (J) BEFORE DETERMINING WH ETHER TO APPROVE THE  ADMINISTRATION 18 
OF PSYCHOTROPIC MEDI CATION , THE COMMITTEE SHALL : 19 
 
  (1) REVIEW THE REPORT GE NERATED BY THE TREAT ING 20 
PSYCHIATRIC PROVIDER  UNDER SUBSECTION (I) OF THIS SECTION ; AND 21 
 
  (2) MEET FOR THE PURPOSE  OF RECEIVING INFORMA TION AND 22 
CLINICALLY ASSESSING  THE INCARCERATED IND IVIDUAL ’S NEED FOR MEDICATIO N 23 
BY: 24 
 
   (I) CONSULTING WITH THE INCARCERATED INDIVID UAL 25 
REGARDING THE REASON  FOR REFUSING THE PSY CHOTROPIC MEDICATION  26 
PRESCRIBED A ND THE INCARCERATED INDIVIDUAL ’S WILLINGNESS TO ACC EPT 27 
ALTERNATIVE TREATMEN T, INCLUDING OTHER MEDI CATION ; 28 
 
6 HOUSE BILL 279   
 
    (II) CONSULTING WITH THE TREATING CLINICIANS WHO ARE 1 
RESPONSIBLE FOR INIT IATING AND IMPLEMENT ING THE INCARCERATED  2 
INDIVIDUAL ’S TREATMENT PLAN ABO UT THE CURRENT TREATM ENT PLAN AND 3 
ALTERNATIVE MODES OF  TREATMENT , INCLUDING MEDICATION , THAT HAVE BEEN 4 
CONSIDERED ; 5 
 
   (III) RECEIVING INFORMATIO N PRESENTED BY THE 6 
INCARCERATED INDIVID UAL AND OTHER INDIVI DUALS PARTICIPATING IN THE 7 
COMMITTEE ; 8 
 
   (IV) PROVID ING THE INCARCERATED  INDIVIDUAL WITH AN 9 
OPPORTUNITY TO ASK Q UESTIONS OF ANYONE P RESENTING INFORMATIO N TO THE 10 
COMMITTEE ; AND 11 
 
   (V) REVIEWING THE CONSEQ UENCES OF REQUIRING THE 12 
ADMINISTRATION OF PS YCHOTROPIC MEDICATIO N AND THE CONSEQUENC ES OF 13 
CONTINUED REFU SAL OF PSYCHOTROPIC MEDICATION . 14 
 
 (K) THE COMMITTEE MAY APP ROVE THE ADMINISTRAT ION OF 15 
PSYCHOTROPIC MEDICAT ION AND MAY RECOMMEN D AND APPROVE ALTERN ATIVE 16 
MEDICATION , IF THE COMMITTEE DET ERMINES THAT : 17 
 
  (1) THE MEDICATION IS PR ESCRIBED BY A PSYCHI ATRIC PROVI DER 18 
FOR THE PURPOSE OF T REATING THE INCARCER ATED INDIVIDUAL ’S MENTAL 19 
DISORDER ; 20 
 
  (2) THE ADMINISTRATION O F PSYCHOTROPIC MEDIC ATION 21 
REPRESENTS A REASONA BLE EXERCISE OF PROF ESSIONAL JUDGMENT ; AND 22 
 
  (3) WITHOUT THE MEDICATI ON, THE INCARCERATED IND IVIDUAL IS  23 
AT SUBSTANTIAL RISK OF CONTINUED SELF –HARM AND DANGEROUS B EHAVIORS 24 
RESULTING FROM THE I NDIVIDUAL : 25 
 
   (I) REMAINING SERIOUSLY MENTALLY ILL WITH NO  26 
SIGNIFICANT RELIEF O F THE PSYCHIATRIC SY MPTOMS THAT : 27 
 
    1. CAUSE THE INCARCERAT ED INDIVIDUAL TO BE A 28 
DANGE R TO SELF OR OTHERS WHILE IN THE LICENSE D MENTAL HEALTH INFI RMARY ; 29 
OR 30 
 
    2. WOULD CAUSE THE INCA RCERATED INDIVIDUAL TO 31 
BE A CONTINUED DANGE R TO SELF AND OTHER INCARCERATED INDIVID UALS IF 32 
DISCHARGED FROM THE LICENSED MENTAL HEAL TH INFIRMARY ; OR 33 
 HOUSE BILL 279  7 
 
  
   (II) RELAPSING INTO A CON DITION IN WHICH THE 1 
INCARCERATED INDIVID UAL IS UNABLE TO PRO VIDE FOR THE INDIVID UAL’S OWN 2 
ESSENTIAL HUMAN NEED S OF HEALTH AND SAFE TY. 3 
 
 (L) (1) THE COMMITTEE SHALL B ASE ITS DECISION ON ITS CLINICAL 4 
ASSESSMENT OF THE IN FORMATION CONTAINE D IN THE INCARCERATE D 5 
INDIVIDUAL ’S RECORD AND INFORMA TION PRESENTED TO TH E COMMITTEE . 6 
 
  (2) THE COMMITTEE SHALL M EET PRIVATELY TO REN DER A 7 
DECISION . 8 
 
 (M) (1) THE COMMITTEE SHALL D OCUMENT ITS CONSIDER ATION OF THE 9 
ISSUES AND THE BASIS  FOR ITS DECISION ON THE ADMINISTRATION OF  10 
PSYCHOTROPIC MEDICAT ION. 11 
 
  (2) THE COMMITTEE SHALL P ROVIDE A WRITTEN DEC ISION ON THE 12 
ADMINISTRATION OF PS YCHOTROPIC MEDICATIO N, WHICH SHALL BE PROVI DED TO 13 
THE INCARCERATED IND IVIDUAL , THE LAY ADVISOR , AND THE INCARCERATED  14 
INDIVIDUAL ’S TREATMENT TEAM FOR I NCLUSION IN THE MEDI CAL RECORD . 15 
 
  (3) IF THE COMMITTEE APPR OVES THE ADMINISTRAT ION OF 16 
PSYCHOTROPIC MEDICAT ION, THE DECISION SHALL S PECIFY : 17 
 
   (I) THE PSYCHOTROPIC MED ICATION APPROVED AND  THE 18 
DOSAGE AND FREQUENCY  RANGE ; 19 
 
   (II) THE D URATION OF THE APPRO VAL, NOT TO EXCEED THE 20 
MAXIMUM TIME ALLOWED  UNDER SUBSECTION (Q) OF THIS SECTION ; AND 21 
 
   (III) THE REASON THAT ALTE RNATIVE TREATMENTS , INCLUDING 22 
OTHER MEDICATION , WERE REJECTED BY THE  COMMITTEE . 23 
 
  (4) IF THE COMMITTEE APPR OVES THE ADM INISTRATION OF 24 
PSYCHOTROPIC MEDICAT ION, THE DECISION SHALL C ONTAIN NOTICE OF THE  RIGHT 25 
TO REQUEST AN ADMINI STRATIVE HEARING AND  APPEAL UNDER SUBSECT IONS (O) 26 
AND (P) OF THIS SECTION . 27 
 
 (N) IF THE COMMITTEE APPR OVES THE ADMINISTRAT ION OF 28 
PSYCHOTROPIC MEDICAT ION, THE LAY ADVISOR PROM PTLY SHALL : 29 
 
8 HOUSE BILL 279   
 
   (1) INFORM THE INCARCERA TED INDIVIDUAL OF TH E RIGHT TO 1 
REQUEST AN ADMINISTR ATIVE HEARING AND AP PEAL THE DECISION UN DER 2 
SUBSECTIONS (O) AND (P) OF THIS SECTION ; AND 3 
 
  (2) ADVISE THE INCARCERA TED INDIVIDUAL OF TH E PRO VISION FOR 4 
RENEWAL OF AN APPROV AL UNDER SUBSECTION (Q) OF THIS SECTION . 5 
 
 (O) (1) AN INDIVIDUAL MAY REQ UEST AN ADMINISTRATI VE HEARING TO 6 
APPEAL THE COMMITTEE ’S DECISION BY FILING  A REQUEST FOR HEARIN G WITH THE 7 
DIRECTOR OF MENTAL HEALTH FOR THE DEPARTMENT OR THE DIRECTOR ’S 8 
DESIGNEE WITHIN 72 HOURS OF RECEIPT OF THE DECISION OF THE COMMITTEE . 9 
 
  (2) WITHIN 24 HOURS OF RECEIPT OF A REQUEST FOR HEARIN G, THE 10 
DIRECTOR OF MENTAL HEALTH OR THE DIRECTOR ’S DESIGNEE SHALL FOR WARD 11 
THE REQUEST TO THE OFFICE OF ADMINIST RATIVE HEARINGS . 12 
 
  (3) (I) AN INITIAL COMMITTEE DECISION AUTHORIZING  THE 13 
ADMINISTRATION OF ME DICATION SHALL BE ST AYED FOR 72 HOURS . 14 
 
   (II) IF A REQUEST FOR HEAR ING IS FILED UNDER T HIS 15 
SUBSECTION , THE STAY SHALL REMAI N IN EFFECT UNTIL TH E ISSUANCE OF THE  16 
ADMINISTRATIVE DECIS ION. 17 
 
  (4) THE OFFICE OF ADMINISTRATIVE HEARINGS SHALL CONDUC T A 18 
HEARING AND ISSUE A DECISION WITHIN 10 CALENDAR DAYS OF THE  DECISION BY 19 
THE COMMITTEE . 20 
 
  (5) THE ADMINISTRATIVE HE ARING MAY BE POSTPON ED BY 21 
AGREEMENT OF THE PAR TIES OR FOR GOOD CAUSE SHOWN . 22 
 
  (6) THE ADMINISTRATIVE LA W JUDGE SHALL CONDUC T A DE NOVO 23 
HEARING TO DETERMINE  WHETHER THE STANDARD S AND PROCEDURES IN THIS 24 
SECTION HAVE BEEN ME T. 25 
 
  (7) AT THE HEARING , THE INDIVIDUAL REPRE SENTING THE 26 
FACILITY : 27 
 
   (I) MAY INTRODUC E THE DECISION OF TH E COMMITTEE AS 28 
EVIDENCE ; AND 29 
 
   (II) SHALL PROVE , BY A PREPONDERANCE O F THE EVIDENCE , 30 
THAT THE STANDARDS A ND PROCEDURES OF THI S SECTION HAVE BEEN MET. 31 
 
 HOUSE BILL 279  9 
 
   (8) THE ADMINISTRATIVE LA W JUDGE SHALL STATE ON THE RECORD 1 
THE FINDINGS OF FACT  AND CONCLUSIONS OF L AW. 2 
 
  (9) THE DETERMINATION OF THE ADMINISTRATIVE L AW JUDGE IS A 3 
FINAL DECISION FOR T HE PURPOSE OF JUDICI AL REVIEW OF A FINAL  DECISION 4 
UNDER THE ADMINISTRATIVE PROCEDURE ACT. 5 
 
 (P) (1) WITHIN 14 CALENDAR DAYS FROM T HE DECISION OF THE 6 
ADMINISTRATIVE LAW JU DGE, THE INDIVIDUAL OR TH E FACILITY MAY APPEA L THE 7 
DECISION TO THE CIRC UIT COURT ON THE REC ORD FROM THE HEARING  8 
CONDUCTED BY THE OFFICE OF ADMINISTRATIVE HEARINGS . 9 
 
  (2) THE SCOPE OF REVIEW S HALL BE AS A CONTEST ED CASE UNDER 10 
THE ADMINISTRATIVE PROCEDURE ACT. 11 
 
  (3) (I) REVIEW SHALL BE ON TH E AUDIOPHONIC TAPE W ITHOUT 12 
THE NECESSITY OF TRA NSCRIPTION OF THE TA PE, UNLESS EITHER PARTY TO THE 13 
APPEAL REQUESTS TRAN SCRIPTION OF THE TAP E. 14 
 
   (II) A REQUEST FOR TRANSCRI PTION OF THE TAPE SH ALL BE 15 
MADE AT THE TIME THE  APPEAL IS FILED . 16 
 
   (III) THE OFFICE OF ADMINISTRATIVE HEARINGS SHALL 17 
PREPARE THE TRANSCRI PTION PRIOR TO THE A PPEAL HEARING , AND THE PARTY 18 
REQUESTING THE TRANS CRIPTION SHALL BEAR THE COST OF TRANSCRI PTION . 19 
 
  (4) THE CIRCUIT COUR T SHALL HEAR AND ISS UE A DECISION ON AN 20 
APPEAL WITHIN 7 CALENDAR DAYS FROM T HE DATE THE APPEAL W AS FILED . 21 
 
 (Q) (1) ADMINISTRATION OF PSY CHOTROPIC MEDICATION  IN 22 
ACCORDANCE WITH THIS  SECTION MAY NOT BE A PPROVED FOR LONGER T HAN 90 23 
DAYS . 24 
 
  (2) (I) BEFORE EXP IRATION OF AN APPROV AL PERIOD UNDER 25 
PARAGRAPH (1) OF THIS SUBSECTION , IF THE INCARCERATED INDIVIDUAL 26 
CONTINUES TO REFUSE PSYCHOTROPIC MEDICAT ION, A COMMITTEE MAY BE 27 
CONVENED TO DECIDE W HETHER RENEWAL IS WA RRANTED . 28 
 
   (II) IF A COMMITTEE APPROV ES THE RENEW AL OF THE 29 
ADMINISTRATION OF PS YCHOTROPIC MEDICATIO N, THE ADMINISTRATION O F 30 
MEDICATION NEED NOT BE INTERRUPTED WHEN THE INCARCERATED IND IVIDUAL 31 
REQUESTS ADMINISTRAT IVE REVIEW OF THE RE NEWAL . 32 
 
10 HOUSE BILL 279   
 
  (R) WHEN PSYCHOTROPIC MED ICATION IS ORDERED I N ACCORDANCE WITH 1 
THIS SECTION , NOT LESS FREQUENTLY THAN EVERY 15 DAYS , THE TREATING 2 
PRACTITIONER SHALL D OCUMENT ANY KNOWN BE NEFITS OF TAKING THE  3 
MEDICATION TO THE IN CARCERATED INDIVIDUA L AND SIDE EFFECTS O F THE 4 
MEDICATION THAT AFFE CT THE INCARCERATED INDIVIDUAL . 5 
 
 SECTION 2 . AND BE IT FURTHER ENACTED, That this Act shall take effect July 6 
1, 2026.  7 
 